Hızlı Erişim


Bu Dergi DOI ve Crosscheck üyesidir


Abstract


CLINICAL FACTORS PREDICTING RESPONSE TO REGORAFENIB IN METASTATIC COLORECTAL CANCER

Colorectal cancer (CRC) is a common disease with high mortality. Regorafenib (Stivarga ®) is an oral small molecule, multiple kinase inhibitor approved worldwide for use in metastatic colorectal cancer. In our study, clinical factors predicting response to regorafenib were investigated. Patients who applied to Gaziantep Medical Park Hospital and Sanko University Medical Faculty Hospital Medical Oncology outpatient clinic between 2010-2021 with the diagnosis of mCRC and using regorafenib were included in the study. Electronic medical records of the patients were reviewed retrospectively. Statistical analyzes were performed using SPSS version 15.0 software. A total of 20 patients with metastatic colorectal cancer using regorafenib in the third or fourth line therapy were included in the study. Overall, 15 (75%) patients had liver metastases. The median overall survival of the patients was 25.5 months (95% Confidence Interval (CI), 24.1-26.8). Overall survival was not significantly associated with sex, ECOG performance status score, de novo metastatic disease status, smoking status and weight loss history (p=0.139, p=0.240, p=0.173, p=0.911, p=0.923, respectively). A significant association was found between the presence of liver metastasis and survival (p=0.036). The median overall survival was 40.3 months (95% CI, 0-92.6) in patients without liver metastases, and 25 months (95% CI: 13.8-36.2) in patients with liver metastases. In this retrospective study investigating the factors affecting the survival of patients using regorafenib with the diagnosis of mCRC, the presence of liver metastasis was found to be associated with a poor prognosis.



Keywords
Metastatic Colorectal Cancer, Regorafenib, Overall Survival



Kaynakça 1 Kopetz S, Chang G.J., Overman M.J., et al. ; Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: pp. 3677-3683 2 Van Cutsem E, Cervantes A, Adam R, et al. ; ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 Aug;27(8):1386-422. 3 Carter NJ. Regorafenib: a review of its use in previously treated patients with progressive metastatic colorectal cancer. Drugs Aging. 2014;31(1):67–78. 4 Grothey A, Van Cutsem E, Sobrero A, et al. ; Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22. PMID: 23177514. 5 Dhillon S. Regorafenib: A Review in Metastatic Colorectal Cancer. Drugs. 2018 Jul;78(11):1133-1144. 6 https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf, Version 2.2021, 01/21/21. 7 Li J, Qin S, Xu R, et al. ; Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015 Jun;16(6):619-29. 8 Ergun Y, Bal O, Dogan M, Uncu D. Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer? J BUON. 2019 Nov-Dec;24(6):2435-2441. PMID: 31983117. 9 Arai H, Miyakawa K, Denda T, et al. ; Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib. Oncotarget. 2017 Nov 30;8(66):110530-110539. doi: 10.18632/oncotarget.22807. PMID: 29299166; PMCID: PMC5746401. 10 Adenis A, de la Fouchardiere C, Paule B, et al. ; Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer. 2016 Jul 7;16:412. doi: 10.1186/s12885-016-2440-9. Erratum in: BMC Cancer. 2016 Jul 25;16(1):518. PMID: 27389564; PMCID: PMC4936193. 11 Walter T, Hawkins NS, Pollock RF, Colaone F, Shergill S, Ross PJ. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. J Cancer Res Clin Oncol. 2020 Oct;146(10):2575-2587. doi: 10.1007/s00432-020-03315-6. Epub 2020 Jul 27. PMID: 32715436; PMCID: PMC7467965. 12 Van Cutsem E, Martinelli E, Cascinu S, et al. ; Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist. 2019 Feb;24(2):185-192. doi: 10.1634/theoncologist.2018-0072. Epub 2018 Sep 6. PMID: 30190299; PMCID: PMC6369948.

Gelişmiş Arama


Duyurular

    ***********************

    mail mail mail mail mail

    Dergimizin Aralık sayısı 

    (25.12.2021)

    yayınlanmıştır.

    mail mail mail mail mail

    mail mail mail mail mail

    25 Mayıs 2022 tarihinde yayınlanacak sayımız için değerlendirilmek üzere 20 Nisan 2022 tarihine kadar makalenizi sisteme yükleyebilirsiniz!

    mail mail mail mail mail

     



Adres :Göztepe Mah., Beykoz, İstanbul/TURKEY
Telefon : Whatsapp: +90 555 005 92 85 Faks :+90 216 606 32 75
Eposta :info@euroasiajournal.org

Web Yazılım & Programlama Han Yazılım Bilişim Hizmetleri